Results 41 to 50 of about 1,294,431 (344)

Leukemia cutis

Indian Journal of Dermatology, 2012
Leukemia cutis is the infiltration of neoplastic leukocytes or their precursors into the epidermis, the dermis, or the subcutis, resulting in clinically identifiable cutaneous lesions. Leukemia cutis may follow, precede or occur concomitantly with the diagnosis of systemic leukemia.
Angoori G Rao, Indira Danturty
openaire   +3 more sources

Insights into pegRNA design from editing of the cardiomyopathy‐associated phospholamban R14del mutation

FEBS Letters, EarlyView.
This study reveals how prime editing guide RNA (pegRNA) secondary structure and reverse transcriptase template length affect prime editing efficiency in correcting the phospholamban R14del cardiomyopathy‐associated mutation. Insights support the design of structurally optimized enhanced pegRNAs for precise gene therapy.
Bing Yao, Qiangbing Yang, Christian J.B. Snijders Blok, Mark A. Daniels, Pieter A. Doevendans, Raymond Schiffelers, Joost P.G. Sluijter, Zhiyong Lei   +7 more
wiley   +1 more source

STAT3 mutation impacts biological and clinical features of T-LGL leukemia [PDF]

, 2017
STAT3 mutations have been described in 30-40% of T-large granular lymphocyte (T-LGL) leukemia patients, leading to STAT3 pathway activation. Considering the heterogeneity of the disease and the several immunophenotypes that LGL clone may express, the aim
BARILA', GREGORIO, BERNO, TAMARA, BOSCARO, ELISA, CABRELLE, ANNA, CALABRETTO, GIULIA, DE MARCH, ELENA, ERCOLIN, CHIARA, FACCO, MONICA, GATTAZZO, CRISTINA, Lamy, Thierry, LEONCIN, MATTEO, Moignet, Aline, PAGNIN, ELISA, Pastoret, C\ue9dric, PIAZZA, FRANCESCO, Roussel, Mikael, SEMENZATO, GIANPIETRO CARLO, Teolato, Sara, TERAMO, ANTONELLA, TRENTIN, LIVIO, ZAMBELLO, RENATO   +20 more
core   +1 more source

A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome

Haematologica, 2021
FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutation in acute myeloid leukemia (AML) is associated with poor prognosis. We hypothesized that quizartinib, a selective and potent FLT3 inhibitor, with azacitidine (AZA) or low-dose ...
Mahesh Swaminathan, Hagop M Kantarjian, Mark Levis, Veronica Guerra, Gautam Borthakur, Yesid Alvarado, Courtney D DiNardo, Tapan Kadia, Guillermo Garcia-Manero, Maro Ohanian, Naval Daver, Marina Konopleva, Naveen Pemmaraju, Alessandra Ferrajoli, Michael Andreeff, Nitin Jain, Zeev Estrov, Elias J Jabbour, William G Wierda, Sherry Pierce, Maria Rhona Pinsoy, Lianchun Xiao, Farhad Ravandi, Jorge E Cortes   +23 more
doaj   +1 more source

Single‐cell insights into the role of T cells in B‐cell malignancies

FEBS Letters, EarlyView.
Single‐cell technologies have transformed our understanding of T cell–tumor cell interactions in B‐cell malignancies, revealing new T‐cell subsets, functional states, and immune evasion mechanisms. This Review synthesizes these findings, highlighting the roles of T cells in pathogenesis, progression, and therapy response, and underscoring their ...
Laura Llaó‐Cid
wiley   +1 more source

Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. [PDF]

, 2019
Dasatinib, a second-generation BCR-ABL1 tyrosine kinase inhibitor, is approved for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, both as first-line therapy and after imatinib intolerance or ...
Abruzzese, Elisabetta, Cortes, Jorge E, Hochhaus, Andreas, Hughes, Timothy P, Laneuville, Pierre, Lipton, Jeffrey H, Paar, David, Rea, Delphine, Rousselot, Philippe, Shah, Neil P, Snyder, David S   +10 more
core   +2 more sources

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I [PDF]

, 2012
Background: Chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphatic leukemia (Ph + ALL) are caused by the t(9;22), which fuses BCR to ABL resulting in deregulated ABL-tyrosine kinase activity.
Badura, Susanne, Khateb, Mamduh, Mahajna, Jamal, Metodieva, Anna, Mian, Afsar Ali, Najajreh, Yousef, Ottmann, Oliver Gerhard, Ruimi, Nili, Ruthardt, Martin   +8 more
core   +1 more source

Classical meets malignant hematology: a case of acquired εγδβ-thalassemia in clonal hematopoiesis

Haematologica
Hemoglobinopathies including thalassemias are among the most frequent genetic disorders worldwide. Primarily, these entities result from germline variants in the globin gene clusters and their cis-acting regulatory elements, and thus the WHO classifies ...
Armin P. Piehler, Marietta Truger, Jan-Hendrik Kozik, Sandra Weissmann, Martin Schwonzen, Manja Meggendorfer, Wolfgang Kern, Torsten Haferlach, Gregor Hoermann, Claudia Haferlach   +9 more
doaj   +1 more source

Intron‐oriented HTLV‐1 integration in an adult T‐cell leukemia/lymphoma cell line sustains expression of intact ift81 mRNA

FEBS Letters, EarlyView.
In the adult T‐cell leukemia/lymphoma (ATL) cell line ED, the human T‐cell leukemia virus type 1 (HTLV‐1) provirus was integrated into the intron of the ift81 gene in the antisense orientation. Despite this integration, both the intact ift81 and the viral oncogene hbz were simultaneously expressed, likely due to the functional insufficiency of viral ...
Mayuko Yagi, Yuka Hirosawa, Yusaku Sagisaka, Minami Hama, Satoshi Takeda, Jun A. Komano   +5 more
wiley   +1 more source

The clathrin-binding domain of CALM-AF10 alters the phenotype of myeloid neoplasms in mice. [PDF]

, 2012
The PICALM (CALM) gene, whose product is involved in clathrin-mediated endocytosis, has been identified in two recurring chromosomal translocations, involving either MLL or MLLT10 (AF10). We developed a mouse model of CALM-AF10(+) leukemia to examine the
Anastasi, J, Brodsky, FM, Fernald, AA, Le Beau, MM, Stoddart, A, Tennant, TR   +5 more
core   +2 more sources